H. S. Hochster

674 total citations
21 papers, 517 citations indexed

About

H. S. Hochster is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, H. S. Hochster has authored 21 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in H. S. Hochster's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). H. S. Hochster is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). H. S. Hochster collaborates with scholars based in United States and Canada. H. S. Hochster's co-authors include Lowell L. Hart, Ramesh K. Ramanathan, Eric Hedrick, John D. Hainsworth, Barrett H. Childs, A. Shpilsky, SJ Horning, Peter A. Cassileth, Edie Weller and Thomas M. Habermann and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Current Oncology.

In The Last Decade

H. S. Hochster

21 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. S. Hochster United States	12	430	130	112	85	79	21	517
Pamela Biondani Italy	12	341 0.8×	162 1.2×	75 0.7×	71 0.8×	104 1.3×	37	505
Arpine Gevorgyan Italy	10	404 0.9×	236 1.8×	150 1.3×	72 0.8×	148 1.9×	24	546
Jobst C. von Einem Germany	15	456 1.1×	178 1.4×	157 1.4×	116 1.4×	107 1.4×	33	659
Maria K. Beykirch Germany	7	345 0.8×	116 0.9×	95 0.8×	71 0.8×	127 1.6×	11	554
Wolfgang Abenhardt Germany	10	230 0.5×	118 0.9×	151 1.3×	40 0.5×	34 0.4×	26	396
Shozo Mori Japan	11	288 0.7×	201 1.5×	241 2.2×	139 1.6×	138 1.7×	63	688
Rodrigo Ruiz-Soto United States	9	186 0.4×	90 0.7×	92 0.8×	36 0.4×	174 2.2×	19	408
Arndt Stahler Germany	11	417 1.0×	170 1.3×	184 1.6×	90 1.1×	92 1.2×	55	534
A. Scott Jung United States	12	347 0.8×	73 0.6×	218 1.9×	33 0.4×	61 0.8×	19	419
D Hossfeld Germany	11	362 0.8×	181 1.4×	191 1.7×	26 0.3×	104 1.3×	27	614

Countries citing papers authored by H. S. Hochster

Since Specialization

Citations

This map shows the geographic impact of H. S. Hochster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. S. Hochster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. S. Hochster more than expected).

Fields of papers citing papers by H. S. Hochster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. S. Hochster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. S. Hochster. The network helps show where H. S. Hochster may publish in the future.

Co-authorship network of co-authors of H. S. Hochster

This figure shows the co-authorship network connecting the top 25 collaborators of H. S. Hochster. A scholar is included among the top collaborators of H. S. Hochster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. S. Hochster. H. S. Hochster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hochster, H. S., John H. Strickler, Ann M. Kapoun, et al.. (2016). Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). European Journal of Cancer. 69. S29–S30. 21 indexed citations

Bendell, Johanna C., et al.. (2011). KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 29(4_suppl). 534–534. 2 indexed citations

Morris, Luc G.T., H. S. Hochster, & Mark D. DeLacure. (2011). Eyelash Trichomegaly Secondary to Panitumumab Therapy. Current Oncology. 18(3). 145–146. 8 indexed citations

Chaves, Jorge, et al.. (2011). Outcome of intravenous calcium and magnesium (Ca/Mg) in oxaliplatin-containing regimens compared with no Ca/Mg.. Journal of Clinical Oncology. 29(15_suppl). e19681–e19681. 2 indexed citations

Nemunaitis, John, et al.. (2009). 1256 Phase I trial of oral Deforolimus in combination with Bevacizumab in patients with advanced solid tumours. European Journal of Cancer Supplements. 7(2). 137–137. 1 indexed citations

Grothey, Axel, Lowell L. Hart, K. M. Rowland, et al.. (2008). Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. Journal of Clinical Oncology. 26(15_suppl). 4010–4010. 76 indexed citations

Kindler, Hedy L., Tara C. Gangadhar, Theodore Karrison, et al.. (2008). Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). Journal of Clinical Oncology. 26(15_suppl). 4502–4502. 31 indexed citations

Cohen, Deirdre Jill, et al.. (2008). Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): Preliminary results on toxicity and K-ras status. Journal of Clinical Oncology. 26(15_suppl). 15060–15060. 1 indexed citations

Kindler, Hedy L., Kathryn Bylow, H. S. Hochster, et al.. (2006). A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis. Journal of Clinical Oncology. 24(18_suppl). 4040–4040. 15 indexed citations

10.

Hochster, H. S., Lowell L. Hart, Ramesh K. Ramanathan, et al.. (2006). Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of Clinical Oncology. 24(18_suppl). 3510–3510. 107 indexed citations

11.

Hochster, H. S., Lauri Welles, Ramesh K. Ramanathan, et al.. (2005). Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies. Journal of Clinical Oncology. 23(16_suppl). 3515–3515. 40 indexed citations

12.

Chang, Richard L., Aleksandar Berić, Leonard Liebes, et al.. (2005). A phase I study of oxaliplatin (OX) in combination with bortezomib (B) in patients with advanced malignancy. Journal of Clinical Oncology. 23(16_suppl). 9678–9678. 1 indexed citations

13.

Colocci, Natalia, Edie Weller, H. S. Hochster, et al.. (2005). Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab. Journal of Clinical Oncology. 23(16_suppl). 6526–6526. 4 indexed citations

14.

Dragovich, Tomislav, Heinz‐Josef Lenz, Caio Max S. Rocha Lima, et al.. (2004). Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. Journal of Clinical Oncology. 22(14_suppl). 3591–3591. 4 indexed citations

15.

Welles, Lauri, H. S. Hochster, R. K. Ramanathan, et al.. (2004). Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) (“Tree” study). Journal of Clinical Oncology. 22(14_suppl). 3537–3537. 4 indexed citations

16.

Hochster, H. S., Edie Weller, Thomas M. Ryan, et al.. (2004). Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Journal of Clinical Oncology. 22(14_suppl). 6502–6502. 59 indexed citations

17.

Wasserheit, Carolyn, Ruth Oratz, Joan Sorich, et al.. (1996). Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity.. Journal of Clinical Oncology. 14(7). 1993–1999. 73 indexed citations

18.

Oratz, Ruth, Matthew Dugan, Daniel F. Roses, et al.. (1991). Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.. PubMed. 51(14). 3643–7. 19 indexed citations

19.

Hochster, H. S. & Peter A. Cassileth. (1990). Fludarabine phosphate therapy of non-Hodgkin's lymphoma.. PubMed. 17(5 Suppl 8). 63–5. 22 indexed citations

20.

Walsh, Christine, J Wernz, H. S. Hochster, et al.. (1989). Phase I study of the combination of alpha-2 interferon and cisplatinum.. PubMed. 8(1). 11–5. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact